The Next Wave of ADC Development: From Precision Engineering to AI-Driven Insights

Dr. Kevin Kolahi is a Physician-Scientist and Anatomic Pathologist at AbbVie, where he leads a cross-functional team of scientists and engineers developing artificial intelligence tools to advance precision medicine and companion diagnostics. Dr. Kolahi has authored over 40 peer-reviewed publications, including first-author papers spanning developmental biology, molecular physiology, oncology, diagnostic pathology, and applied AI in healthcare. He was awarded the NIH Ruth L. Kirschstein NRSA Individual Fellowship (F30) during his MD/PhD training. He earned his MD and PhD through the Medical Scientist Training Program at Oregon Health & Science University, and completed an Anatomic Pathology residency and Gynecologic Pathology fellowship at Stanford University.

Dr Aliki Taylor is an Executive Director at Gilead Sciences based in the UK and leads Real World Evidence Oncology. In this role, she leads the strategy and implementation of real-world oncology studies in Oncology across the Gilead portfolio from early development to post-launch activities. Aliki has been in the pharmaceutical industry for 16 years, with a previous leadership role in Epidemiology in the field of Oncology at AstraZeneca, Takeda, and Amgen. Prior to joining the industry, Aliki worked in academia and completed a Cancer Research UK Training Fellowship and a PhD in cancer epidemiology. Her original training and qualifications are in medicine, qualifying from UCL in London as a doctor and working in the NHS for 8 years. She has also completed her higher specialist training and qualifications in Public Health Medicine.

Dr. Kate Sasser is the Chief Scientific Officer of Tempus. Dr. Sasser brings over 20 years of experience in translational research and precision medicine in biological sciences across academia and the pharmaceutical and biotech industry. Prior to Tempus, she led the translational research, precision medicine, and R&D operations organizations within Genmab, a biotech company focused on developing transformative antibody therapeutics as medicine. She also led translational research for oncology at Johnson and Johnson (Janssen PRD), using translational and data science approaches to accelerate clinical development. Dr. Sasser graduated from Oregon State University with a BS in Microbiology, and received her PhD in integrated biomedical sciences from Ohio State University.

Razik Yousfi is the SVP and GM of AI Products at Tempus, where he leads multi-modal Foundation Model initiatives and the development of AI products for Life Sciences and clinical care. He previously served as CEO and CTO of Paige AI, a pioneer in AI for computational pathology, through its acquisition by Tempus in 2025. Razik is recognized for bridging deep technical expertise with executive leadership to deliver high-impact, AI-enabled solutions. A proponent of lean product development, he specializes in building and motivating cross-functional teams to solve complex problems. He is driven by a passion for creating customer-centric products at the intersection of data and AI—ultimately advancing a new generation of precision medicine tests that improve patient outcomes.